---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-010869"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-05-27T23:59:59+00:00"
generated_at: "2026-06-25T06:25:09.987060+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics stockholders approve doubling authorized common stock to 300M shares

## Summary
- Shareholders approved amendment to increase authorized common shares from 150M to 300M (93,032,987 for, 758,293 against).
- Directors elected: Alexis Borisy, Mark Murcko, Laura Shawver (class II, three-year term).
- Non-binding advisory vote on executive compensation passed (83,645,401 for, 3,551,366 against).
- Ratification of Ernst & Young as independent auditor for FY2022 approved (93,772,475 for, 15,739 against).

## SEC filing metadata
- accession: 0000950170-22-010869
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022010869/0000950170-22-010869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022010869/rlay-20220527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-010869
- JSON: https://secwatch.observer/filing/0000950170-22-010869.json
- Plain text: https://secwatch.observer/filing/0000950170-22-010869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.